Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AK119 |
Synonyms | |
Therapy Description |
AK119 is a monoclonal antibody targeting CD73, which may lead to decreased adenosine via inhibition of the conversion of adenosine monophosphate (AMP) to adenosine, potentially resulting in anti-tumor activity (J Clin Oncol 2021 39:15_suppl, TPS2675). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AK119 | AK 119|AK-119|Dresbuxelimab | CD73 Antibody 12 | AK119 is a monoclonal antibody targeting CD73, which may lead to decreased adenosine via inhibition of the conversion of adenosine monophosphate (AMP) to adenosine, potentially resulting in anti-tumor activity (J Clin Oncol 2021 39:15_suppl, TPS2675). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|